Aspirin for DVT Prophylaxis

Primary Prophylaxis Settings

The American College of Chest Physicians (ACCP) guidelines state that aspirin is not recommended as primary DVT prophylaxis in most clinical settings, as it is significantly less effective than anticoagulants, but may be considered in select scenarios, such as low-risk orthopedic surgery patients, secondary prevention after stopping anticoagulation for unprovoked VTE, or in low-risk multiple myeloma patients 1, 2
The American College of Chest Physicians (ACCP) and the National Comprehensive Cancer Network (NCCN) guidelines advise against using aspirin as the sole method of thromboprophylaxis in hospitalized medical or surgical patients due to inferior efficacy compared to anticoagulants 3, 4
The NCCN guidelines state that aspirin is not considered effective VTE prophylaxis in general settings, with the Women's Health Study showing no significant reduction in VTE incidence over 10 years in healthy women 3, 5

The American College of Chest Physicians (ACCP) guidelines suggest using aspirin over no treatment to reduce recurrent VTE risk if a patient decides to stop anticoagulation after unprovoked proximal DVT or PE, with a weak recommendation and low-certainty evidence showing aspirin reduces recurrent VTE by 53 fewer events per 1,000 cases over 2-4 years compared to placebo 1, 2
The CHEST guidelines provide a critical caveat that aspirin is NOT a reasonable alternative to continued anticoagulation, as reduced-dose DOACs prevent 46 more VTE events per 1,000 cases compared to aspirin with similar bleeding risk 1, 2

The National Comprehensive Cancer Network (NCCN) guidelines advise against using aspirin as sole prophylaxis in high-risk patients, such as those with active cancer, prior VTE, hypercoagulable states, or prolonged immobility 3, 4

The 2021 CHEST guidelines provide direct comparisons showing anticoagulants' superiority, with reduced-dose DOAC vs aspirin resulting in 46 fewer VTE events per 1,000 cases with only 4 more bleeding events 1, 2
The 2021 CHEST guidelines also compare rivaroxaban vs aspirin, resulting in 39 fewer VTE events per 1,000 cases with 4 more major bleeds 1, 2

The American Academy of Orthopaedic Surgeons (AAOS) recommends aspirin as an acceptable sole prophylactic agent (Grade B recommendation) for standard-risk patients after hip replacement, prioritizing symptomatic outcomes over asymptomatic DVT rates detected by imaging 6
The Scottish Intercollegiate Guidelines Network (SIGN) and Brazilian guidelines also endorse aspirin monotherapy (Grade A recommendations) for standard-risk patients after hip replacement, prioritizing symptomatic outcomes over asymptomatic DVT rates detected by imaging 6
The American College of Chest Physicians (ACCP) explicitly advises against aspirin as the sole method of thromboprophylaxis (Grade A recommendation) for patients after hip replacement, stating it is significantly less effective than other anticoagulant regimens 6
The French guidelines similarly recommend against aspirin monotherapy (Grade B) for patients after hip replacement 6

Aspirin was found to be noninferior to low-molecular-weight heparin (LMWH) for extended VTE prophylaxis after initial 10 days of LMWH following total hip arthroplasty 7

The ACCP recommends that patients with lower‑extremity trauma requiring immobilization receive low‑molecular‑weight heparin (LMWH) rather than aspirin as the primary method of thromboprophylaxis; LMWH should be started before or as soon as possible after surgery. 8
Standard prophylactic LMWH dosing (e.g., enoxaparin 40 mg subcutaneously once daily or 30 mg twice daily) is advised, with a minimum treatment duration of 7–10 days and continuation throughout the entire period of immobilization and non‑weight‑bearing status. 8
The ACCP emphasizes that pharmacologic prophylaxis must be maintained for the whole non‑weight‑bearing period; stopping after the initial 7–10 days is insufficient. 8
Clinicians should not wait for clinical signs of DVT/PE before escalating prophylaxis, as delayed treatment can lead to fatal pulmonary embolism. 8

Randomized trials of aspirin for VTE prevention have been limited to elective hip/knee arthroplasty and hip‑fracture surgery; no high‑quality data support its use in trauma surgery such as tibial plateau fixation. [9][10]11
The PEP trial (using 160 mg aspirin daily) demonstrated a 36 % relative reduction in symptomatic DVT/PE in elective joint‑replacement patients, but this dose is higher than the 81 mg low‑dose regimen commonly used for cardiovascular protection. [9][10]11
Even in the arthroplasty studies, aspirin was associated with higher rates of asymptomatic DVT on screening compared with anticoagulants, indicating inferior efficacy. [10][11]
Because the clinical context of tibial plateau fracture surgery involves combined trauma, surgery, and prolonged immobilization, aspirin’s limited efficacy in elective orthopaedic procedures does not translate to this high‑risk scenario. [9][10]11

LMWH – First‑line agent; start immediately peri‑operatively and continue throughout immobilization. (Dose and duration as above.) 8
Fondaparinux – Alternative when LMWH is contraindicated; 2.5 mg subcutaneously once daily. 12
Low‑dose unfractionated heparin – Another alternative, though it requires more intensive monitoring. 8
Direct oral anticoagulants (DOACs) – May be used in reduced prophylactic doses when LMWH or fondaparinux are unsuitable (guideline‑based dosing not detailed in the cited sources).

Intermittent pneumatic compression (IPC) devices applied to the contralateral leg are recommended as adjunctive therapy, especially when bleeding risk limits pharmacologic options; mechanical methods carry no bleeding risk but should not replace anticoagulation in high‑risk patients. 12

Assuming that low‑dose (81 mg) aspirin provides adequate protection because it is “safer”; the dose studied for VTE prevention is higher, and aspirin is less effective than anticoagulants in trauma settings. [9][10]11
Discontinuing anticoagulation after the initial 7–10 day postoperative window despite ongoing non‑weight‑bearing status. 8
Relying solely on symptom‑driven escalation of prophylaxis rather than proactive anticoagulation. 8